Sunday, 16 April 2017

Detailed Report on Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021

Report Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021 is a new market research publication announced by Reportstack. 
Report Outline: PAH in the arteries, which carry blood from the heart to the lungs, occurs when blood vessels become narrow, making blood flow difficult.
For detailed report with TOC, please click here ​Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021
Market Growth: The global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021.
Key vendors • Actelion Pharmaceuticals
• GlaxoSmithKline
• Novartis
• United Therapeutics
Other prominent vendors • AADi
• Actelion Pharmaceuticals
• Aires Pharmaceuticals
• Arena Pharmaceuticals
• Asklepion Pharmaceuticals
• AstraZeneca
• Bayer Healthcare
• Berlin Cures
• DEKA Research & Development
• Dong- A ST
• Eiger BioPharmaceuticals
• Gilead Sciences
• Lung Biotechnology
• Merck 
• Northern Therapeutics
• Pfizer 
• PhaseBio Pharmaceuticals
• Radikal Therapeutics
• Reata Pharmaceuticals
• SteadyMed Therapeutics
• Velo Bio
Regions Covered:  
• Americas
Companies Mentioned
Actelion Pharmaceuticals, DAIICHI SANKYO, GlaxoSmithKline, Novartis, United Therapeutics, AADi, Actelion Pharmaceuticals, Aires Pharmaceuticals, Arena Pharmaceuticals, Asklepion Pharmaceuticals, AstraZeneca, Bayer Healthcare, Berlin Cures, BIAL, DEKA Research & Development, Dong- A ST, Eiger BioPharmaceuticals, Gilead Sciences, Lung Biotechnology, Merck, Northern Therapeutics, Pfizer, PhaseBio Pharmaceuticals, Radikal Therapeutics, Reata Pharmaceuticals, SteadyMed Therapeutics, and Velo Bio.
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research

No comments:

Post a Comment